Payment overview · 2025
General Payments
$3,741.00
96 reported records · 25 companies
Healthcare provider profile · identity verified
Alexander Runowski, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BATTLE CREEK, MI · NPI 1154439339
Verified facts
What the public records show
CMS Open Payments records show Alexander Runowski, M.D. received $3,741.00 in general payments during 2025 across 96 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $633.71 | 16.9% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $572.78 | 15.3% | 16 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $386.63 | 10.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $276.87 | 7.4% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $265.81 | 7.1% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $164.89 | 4.4% | 7 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$163.06 | 4.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $146.53 | 3.9% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $140.90 | 3.8% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $130.16 | 3.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $126.47 | 3.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $120.13 | 3.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $101.16 | 2.7% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $74.75 | 2.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $69.32 | 1.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.12 | 1.6% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $50.98 | 1.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.39 | 1.4% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $50.03 | 1.3% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $46.13 | 1.2% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $29.74 | 0.8% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $22.13 | 0.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.11 | 0.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.34 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.86 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,741.00 | 96 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $405.24 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $386.63 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $299.19 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $273.59 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $265.81 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $164.89 | 7 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $163.06 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $159.95 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $156.47 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $154.53 | 8 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $132.90 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $130.16 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $120.13 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $120.13 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $120.04 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $101.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.54 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $74.75 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $60.12 | 3 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $51.08 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $50.98 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $50.03 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $46.13 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $29.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $12.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $12.25 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 183 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
183 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 398 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 373 | 64 |
| Potassium Chloride | Potassium Chloride | 283 | 71 |
| Furosemide | Furosemide | 254 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 62 |
| Gabapentin | Gabapentin | 231 | 45 |
| Sertraline Hcl | Sertraline Hcl | 224 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 55 |
| Eliquis | Apixaban | 183 | 36 |
| Losartan Potassium | Losartan Potassium | 153 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 37 |
| Metformin Hcl | Metformin Hcl | 147 | 31 |
| Lisinopril | Lisinopril | 144 | 32 |
| Omeprazole | Omeprazole | 137 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 53 |
| Trazodone Hcl | Trazodone Hcl | 127 | 36 |
| Carvedilol | Carvedilol | 126 | 24 |
| Donepezil Hcl | Donepezil Hcl | 126 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 23 |
| Buspirone Hcl | Buspirone Hcl | 106 | 33 |
| Divalproex Sodium | Divalproex Sodium | 103 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 26 |
| Memantine Hcl | Memantine Hcl | 98 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 23 |
| Famotidine | Famotidine | 83 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 27 |
| Levetiracetam | Levetiracetam | 77 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 13 |
| Myrbetriq | Mirabegron | 75 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 73 | 13 |
| Olanzapine | Olanzapine | 73 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | suppressed |
| Prednisone | Prednisone | 65 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 19 |
| Enulose | Lactulose | 63 | suppressed |
| Jardiance | Empagliflozin | 63 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 63 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 45 |
| Baclofen | Baclofen | 60 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 17 |
| Finasteride | Finasteride | 59 | 11 |
| Bumetanide | Bumetanide | 57 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 12 |
| Azithromycin | Azithromycin | 56 | 47 |
| Nystatin | Nystatin | 55 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 11 |
| Mirtazapine | Mirtazapine | 53 | 17 |
| Cephalexin | Cephalexin | 52 | 40 |
| Ezetimibe | Ezetimibe | 52 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 11 |
| Risperidone | Risperidone | 49 | 11 |
| Chlorthalidone | Chlorthalidone | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 24 |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Alprazolam | Alprazolam | 42 | 29 |
| Simvastatin | Simvastatin | 42 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 11 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Fluconazole | Fluconazole | 38 | 29 |
| Spironolactone | Spironolactone | 38 | 13 |
| Primidone | Primidone | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Dexamethasone | Dexamethasone | 32 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 29 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Allopurinol | Allopurinol | 30 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | 11 |
| Lorazepam | Lorazepam | 27 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Atenolol | Atenolol | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 15 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Scopolamine | Scopolamine | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | 12 |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Loteprednol Etabonate | Loteprednol Etabonate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,741.00 · 96 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, DUPIXENT, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, INGREZZA, JARDIANCE, Leqembi, MOUNJARO, NUPLAZID, NURTEC ODT, Nayzilam, OTEZLA, Ohtuvayre, Ozempic, PROLIA, REPATHA, REXULTI, TRELEGY ELLIPTA, VALTOCO, VOWST, VRAYLAR, VYEPTI, Wegovy, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error